First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Mirvetuximab Soravtansine in Adults With Ovarian Cancer and Other Folate Receptor 1 (FOLR1)-Positive Solid Tumors
Clinical trial NCT01609556 · COMPLETED
Trial details
- NCT number
- NCT01609556
- Sponsor
- ImmunoGen, Inc.
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2012-06-28
- Primary completion
- 2018-03-19
- Enrollment
- 206
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.